Eli Lilly’s 2023 guidance: Up to 4 new drugs on the way

Looking ahead to next year, Eli Lilly is banking on the launch of up to four new medicines to continue its growth trajectory.

The pharma giant released its 2023 financial guidance Tuesday, projecting revenue between $30.3 billion and $30.8 billion, driven by volume increases from key growth products, as well as full-year earnings per share in the range of $7.65 to $7.85 on a reported basis.